scholarly journals CRM1, a novel independent prognostic factor overexpressed in invasive breast carcinoma of poor prognosis

2018 ◽  
Author(s):  
Lu Yue ◽  
Zhen‑Ni Sun ◽  
Ya‑Sai Yao ◽  
Zan Shen ◽  
Hai‑Bo Wang ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Breast Carcinoma ◽  
Poor Prognosis ◽  
Independent Prognostic Factor ◽  
Invasive Breast Carcinoma

scholarly journals S-phase Fraction as an Independent Prognostic Factor in Invasive Breast Carcinoma -A Study of Long-term Follow-up

2007 ◽  
Vol 10 (1) ◽  
pp. 36
Author(s):  
Jin Hae Bae ◽  
Jeong Won Bae ◽  
Sang Uk Woo ◽  
Chul Whan Kim ◽  
Jae Bok Lee ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Breast Carcinoma ◽  
S Phase ◽  
Independent Prognostic Factor ◽  
Invasive Breast Carcinoma ◽  
Phase Fraction ◽  
Long Term Follow Up

scholarly journals Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma

2016 ◽  
Vol 468 (4) ◽  
pp. 493-502 ◽  
Author(s):  
Arvydas Laurinavicius ◽  
Benoit Plancoulaine ◽  
Allan Rasmusson ◽  
Justinas Besusparis ◽  
Renaldas Augulis ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Breast Carcinoma ◽  
Independent Prognostic Factor ◽  
Invasive Breast Carcinoma ◽  
Ki67 Expression

scholarly journals Preoperative Plasma Fibrinogen and Serum Albumin Score Is an Independent Prognostic Factor for Resectable Stage II-III Gastric Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Menghui Wu ◽  
Yuchen Pan ◽  
Zhifang Jia ◽  
Yueqi Wang ◽  
Na Yang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Serum Albumin ◽  
Poor Prognosis ◽  
Response Rate ◽  
Prognostic Significance ◽  
Independent Prognostic Factor ◽  
The Other ◽  
Plasma Fibrinogen ◽  
Radical Gastrectomy

Background. Radical gastrectomy with D2 lymphadenectomy is recognized as the standard treatment for resectable advanced gastric cancer. Preoperative fibrinogen and albumin measurements may bring clinical benefits in terms of providing advanced notice of a poor prognosis or recurrence in patients undergoing radical resection. The aim of this study was to identify markers that are predictive of a poor prognosis prior to surgery. Methods. Eight hundred forty-two consecutive patients who underwent curative radical gastrectomy at our hospital between 2008 and 2012 were retrospectively reviewed. Based on plasma fibrinogen and serum albumin levels, preoperative fibrinogen and albumin scores (Fib-Alb scores) were investigated, and the prognostic significance was determined. Results. The patients were classified according to a Fib-Alb score of 0 (n=376), 1 (n=327), or 2 (n=139). When the correlation between the response rate and the change in the Fib-Alb score was investigated, the response rate was significantly lower in patients with an increased Fib-Alb score than in the other patients. In the survival analysis, patients in the Fib-Alb high-score group exhibited significantly worse recurrence-free survival (RFS) (P=0.030) than patients in the other groups. A multivariate analysis using clinical stage and the change in the Fib-Alb score as covariates revealed that a change in the Fib-Alb score (Fib-Alb score 1, HR: 1.31, 95% CI: 1.03-1.66, P=0.028; Fib-Alb score 2, HR: 1.61, 95% CI: 1.20-2.17, P=0.001) was a significant independent predictive factor for RFS. Conclusions. The prognosis of patients with high fibrinogen and low albumin levels is poor. The Fib-Alb score was shown to be an independent prognostic factor for postoperative recurrence in gastric cancer patients who underwent radical gastrectomy.

scholarly journals 8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis

PLoS ONE ◽  
2009 ◽  
Vol 4 (10) ◽  
pp. e7239 ◽  
Author(s):  
Sylvie Rodrigues-Ferreira ◽  
Anne Di Tommaso ◽  
Ariane Dimitrov ◽  
Sylvie Cazaubon ◽  
Nadège Gruel ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Gene Product ◽  
Poor Prognosis ◽  
Invasive Breast Carcinoma

Circulating tumor cell (CTC) as a significant clinical marker in epithelioid-type malignant pleural mesothelioma (MPM).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7080-7080
Author(s):  
Kazue Yoneda ◽  
Fumihiro Tanaka ◽  
Shunichi Fukuda ◽  
Hayato Orui ◽  
Masaki Hashimoto ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Tumor Cell ◽  
Malignant Pleural Mesothelioma ◽  
Poor Prognosis ◽  
Circulating Tumor Cell ◽  
Independent Prognostic Factor ◽  
Pleural Mesothelioma ◽  
Roc Curve Analysis ◽  
Clinical Marker ◽  
Significant Difference

7080 Background: Circulating tumor cell (CTC) is a surrogate of distant metastasis, and our preliminary study suggested that CTC detected by an EpCAM-based immuno-magnetic separation system (“CellSearch”) was a useful clinical marker in the diagnosis of malignant pleural mesothelioma (MPM) (Tanaka F. et al ASCO 2008). Methods: Patients who presented at our institute to receive pleural biopsy with suspicion of MPM were prospectively enrolled. CTCs in 7.5mL of peripheral blood were quantitatively evaluated with the CellSearch system. Results: Among 136 eligible patients, 104 were finally diagnosed with MPM, and 32 were with non-malignant diseases (NM). CTC was positive (CTC≥1) in 32.7% (37/104) of MPM pts, and in 9.4% (3/32) of NM pts (p=0.011). CTC-count was significantly higher in MPM (range, 0-9) than in NM (range, 0-1; p=0.007). According to a ROC curve analysis, the CTC-test provided a significant diagnostic performance in discrimination between MPM and NM (AUC= 0.623; P=0.036). Among MPM pts, CTC-positivity and CTC-count were significantly increased with tumor progression (p=0.026 and p=0.008, respectively). For all MPM pts, there was no significant difference in overall survival between CTC-positive and negative pts. However, in a planned subset analysis, CTC was a significant factor to predict poor prognosis (median survival time, 8.0 months for CTC-positive pts, and 20.3 months for negative pts; p=0.012) in pts with epithelioid-type MPM in which CTC was exclusively positive; a multivariate analysis confirmed that CTC, along with PS, was an independent prognostic factor (HR=2.38; P=0.006). Conclusions: CTC was a significant diagnostic marker in discrimination between MPM and NM. CTC-positivity was a significant and independent prognostic factor to predict a poor prognosis of epithelioid MPM. [Table: see text]

Stromal Cd10 expression as a potential novel prognostic factor in invasive breast carcinoma

Pathology ◽  
2017 ◽  
Vol 49 ◽  
pp. S64
Author(s):  
Azza Rizk ◽  
Eman Abdelzaher ◽  
Ahmed Gowily ◽  
Rana Elsaka
Keyword(s):  
Prognostic Factor ◽  
Breast Carcinoma ◽  
Invasive Breast Carcinoma ◽  
Cd10 Expression

FOXP3 Expression and Overall Survival in Breast Cancer

2009 ◽  
Vol 27 (11) ◽  
pp. 1746-1752 ◽  
Author(s):  
Andrea Merlo ◽  
Patrizia Casalini ◽  
Maria Luisa Carcangiu ◽  
Chiara Malventano ◽  
Tiziana Triulzi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Prognostic Factor ◽  
Breast Carcinoma ◽  
Survival Probability ◽  
Expression Patterns ◽  
Foxp3 Expression ◽  
Independent Prognostic Factor ◽  
Free Survival ◽  
Node Positive

Purpose The transcription factor forkhead box P3 (FOXP3) up- or downregulates a large number of genes and has been recently reported to be expressed in tumor cells. We investigated the prognostic importance of FOXP3 expression in patients with breast cancer. Patients and Methods The expression patterns of FOXP3 were characterized by immunohistochemistry in primary breast carcinoma specimens from patients of the Milan 3 and 1 trials. Kaplan-Meier analysis and Cox proportional hazards regression modeling were used to assess the overall survival, distant metastasis-free survival, and local relapse cumulative incidence, according to the presence or absence of FOXP3 expression. Results FOXP3 expression in tumors was associated with worse overall survival probability and the risk increased with increasing FOXP3 immunostaining intensity. FOXP3 was also a strong prognostic factor for distant metastases-free survival but not for local recurrence risk. In multivariate analysis FOXP3 resulted an independent prognostic factor and the hazard ratio of FOXP3 expression and of lymph node positivity were similar. In the Milan 3 trial, the probability of 10-year survival in node-negative subgroup was 100% for FOXP3-negative and 82% for FOXP3-positive patients; in node-positive subgroup 82% for FOXP3-negative and 41% for FOXP3-positive patients. Even in the Milan 1 trial the lack of FOXP3 expression in node-positive subgroup was related to a significantly better prognosis than in FOXP3-positive patients (10-year survival probability, 89% v 59%). Conclusion The data identify FOXP3 expression as a new independent prognostic factor in breast carcinoma, which might help to improve the selection of patients for appropriate therapy.

Sign in / Sign up

Export Citation Format

Share Document